申请人:Takeda Pharmaceutical Company Limited
公开号:EP2311842A2
公开(公告)日:2011-04-20
Compounds of the formula:
wherein ring A is heteroaryl, Q is O or S; L is selected from the group consisting of -CHR3-, -NR4- and -O-; X1 and X2 are each independently selected from the group consisting of CR5, and N; and R1, R2, R3, R4, R5 and R5' are defined herein, are provided. The compounds are P13K/mTOR inhibitors and are useful in the treatment of a number of conditions, including cancer and inflammatory diseases.
式中的化合物:
其中环 A 是杂芳基,Q 是 O 或 S;L 选自 -CHR3-、-NR4- 和 -O- 组成的组;X1 和 X2 各自独立地选自 CR5 和 N 组成的组;以及 R1、R2、R3、R4、R5 和 R5' 在此定义。这些化合物是 P13K/mTOR 抑制剂,可用于治疗多种疾病,包括癌症和炎症性疾病。